Because HMGB1-deficient cancers may have limited capacity to recruit inflammatory cells through secretion of HMGB1, it was speculated that TLR4 agonists may be able to substitute HMGB1 in its role of activating T cells by binding to TLR4. This evidence concerns the gene HMGB1 and cancer.